RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Clinical trials for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill targets Hard-to-Treat lymphoma in early human test
Disease control CompletedThis early-stage trial tests an experimental oral drug called DZD8586 in adults with B-cell Non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The study aims to find a safe dose and check whether the drug can shrink tumors. Participants take the …
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New drug combo shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis study tests a drug called mosunetuzumab, given alone or with another drug (atezolizumab), in people with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukemia that has come back or not responded to treatment. The goal is to find the best dose and check safety and effec…
Matched conditions: RELAPSED OR REFRACTORY B CELL NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 26, 2026 16:25 UTC